Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin

... data from a preclinical study, which utilized RNA interference (RNAi) and bioinformatics to identify genetic ... response to brostallicin, a high-throughput RNA interference screen was performed in selected ovarian cancer cell lines. RNA interference is a cellular process that results in the ...

Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research

... announced that the company's TransKingdom RNA interference ( tk RNAi) technology will be the focus of three ... Construct for TransKingdom RNA interference (tkRNAi) 8 am - noon Hall B-F ... (MDR) by TransKingdom RNA interference (tkRNAi) 8 am - noon Hall B-F ...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

... of the knee, including: -- Decreased interference from pain in general activity and normal work, as measured by the BPI Pain interference (BPI-I) scales. -- ... Secondary outcomes included the BPI-Severity and interference items, weekly mean of the 24-hour worst pain and ...

Alfacell Provides Shareholder Update

... Onconase can be used as routine tool to detect the gene silencing via RNA interference (RNAi) mechanism. Currently, there are thousands of researchers ... biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ...

Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models

... -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced study results that demonstrated the ... company dedicated to the development of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial ...

RSV Researcher Makes Gains in Finding Treatments

... Prize winning discovery of RNA interference, or RNAi. "Harnessing RNA interference could be used to conceptually treat many diseases," DeVincenzo said. "RNA interference can theoretically block the production of any disease-causing protein." ...

Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice

... -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced study results that demonstrated the ... company dedicated to the development of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial ...

Benitec MOU With CalbaTech, Inc.

... such mRNA molecules disappear, the corresponding gene is silenced. RNA interference is of great importance for the regulation of gene expression and can be used against viral infections. RNA interference is already being widely used in basic science as a method to study ...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... and Alnylam because each company advanced drugs that incorporate Isis' technology. Isis co-exclusively licensed its single-stranded RNA interference (ssRNAi) technology to Alnylam as part of a new strategic initiative to continue to develop the ssRNAi platform. Regulus achieved its first ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... treatment if symptoms of lupus-like syndrome develop. Do not administer live vaccines or attenuated vaccines concurrently with CIMZIA. interference with certain coagulation assays has been detected in patients treated with CIMZIA. There is no evidence that CIMZIA therapy has an effect on in vivo ...

Quark Pharmaceuticals Presents at Asia TIDES Conference

... FREMONT, Calif., March 9 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development presented an overview of Quark's ...

Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

... FREMONT, Calif., Jan. 8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II clinical trial evaluating its systemically ...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

... and treat a wide range of human disorders - from inflammatory disease to cancer - based on the company's proprietary technology, TransKingdom RNA interference ( tk RNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel ...

Alfacell Provides ONCONASE(R) NDA Submission Update

... Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for ...

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years

... (an interleukin-1 antagonist) and another TNF blocker, with no added benefit. Therefore, the combination of CIMZIA and anakinra is not recommended. interference with certain coagulation assays has been detected in patients treated with CIMZIA. There is no evidence that CIMZIA therapy has an effect on in vivo ...

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

... FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target ...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

... (an interleukin-1 antagonist) and another TNF blocker, with no added benefit. Therefore, the combination of CIMZIA and anakinra is not recommended. interference with certain coagulation assays has been detected in patients treated with CIMZIA. There is no evidence that CIMZIA therapy has an effect on in vivo ...

CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients

... (an interleukin-1 antagonist) and another TNF blocker, with no added benefit. Therefore, the combination of CIMZIA and anakinra is not recommended. interference with certain coagulation assays has been detected in patients treated with CIMZIA. There is no evidence that CIMZIA therapy has an effect on in vivo ...

Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

... Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced QPI-1007 as the Company's first siRNA drug candidate based on its own intellectual property for a host of ...

Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial

... function in kidney transplantation. Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM. About RNAi RNA interference (RNAi), is a Nobel Prize winning technology and one of the most exciting areas of drug discovery today. It represents a completely new approach to ...

Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema

... FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating PF-4523655 ...

Silence Therapeutics Announces Board Changes

... for treatment of acute kidney injury. Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM. About RNAi RNA interference (RNAi), is a Nobel Prize winning technology and one of the most exciting areas of drug discovery today. It represents a completely new approach to ...

Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease

... interleukin-1 antagonist) and another TNF blocker, with no added benefit. Therefore, the combination of Cimzia(R) and anakinra is not recommended. interference with certain coagulation assays has been detected in patients treated with Cimzia(R). There is no evidence that Cimzia(R) therapy has an effect on in ...

Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008

... cells and diseased tissues. In a proprietary process, we modify live, nonpathogenic E. coli bacteria to produce and deposit mediators of RNA interference (short hairpin RNA) directly into the target cells. The nonpathogenic bacteria are subsequently degraded by the host cells without adverse effects, ...

Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach

... siRNA- lipoplexes for cancer therapy." Santel et. al., Gene Therapy(4) 2006 Aug;13(16):1222-34. "A novel siRNA- lipoplex technology for RNA interference in the mouse vascular endothelium." New York Times(5), April 2, 2008. "Study is a Setback for Some RNA-Based Drugs." Adam D. Judge, Gurneet Bola, ...

Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report

... provides confirmation. In 100 percent of the lesions, the PressureWire provided a better physiologic assessment of the pressure gradient, without the interference of the obstruction due to the catheter." "Due to its small size, just 0.014, and high-fidelity transducer, PressureWire is able to provide results ...

Seven-Year Neck Pain Study Sheds Light on Best Care

... that neck pain, including whiplash-related pain, be classified and treated in a common system of 4 grades: Grade 1: neck pain with little or no interference with daily activities Grade 2: neck pain that limits daily activities Grade 3: neck pain accompanied by radiculopathy ("pinched nerve" - ...

Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug

... SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, announced today that it has entered into a collaboration and license agreement with Pfizer Inc. to develop and ...

Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans

... was first published by Quark with the University of Illinois in a breakthrough paper in Science magazine (Science. 1999 Sep 10;285). Using RNA interference technology to temporarily inhibit p53 in acute settings such as acute kidney injury, apoptosis is delayed thereby allowing natural repair mechanisms ...

Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)

... for therapeutic purposes, of the expression of the transcription factor human p53, which is associated with DNA repair and apoptosis. Using RNA interference technology to temporarily inhibit p53 in acute settings such as acute kidney injury, apoptosis is delayed thereby allowing natural repair mechanisms ...

Video: New Research Discovers Independent Brain Networks Control Human Walking

... placed on key joints, researchers found subjects could store different walking patterns for forward versus backward walking simultaneously, with no interference between the two, revealing that separate brain systems control the two directions of walking. Surprisingly, people could also walk easily with one ...

Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain

... were associated with less pain-related sleep interference than in those patients taking sugar pill. Results ... Both doses of Cymbalta reduced pain-related sleep interference at the end of the 12 weeks significantly more ... night pain and reduction in pain sleep interference was demonstrated in a population that was not ...

AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain

... with both Zenvia doses significantly reduced pain interference with daily activities (p less than 0.0001), ... with both Zenvia doses significantly reduced pain interference with daily activities compared with placebo ... with both Zenvia doses significantly reduced pain interference with sleep compared with placebo (p less ...

Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles

... The poster presentation, "Bacteria deliver RNA interference in vitro and in vivo for cancer therapy: tkRNAi," ... hall. About tkRNAi(TM)- TransKingdom RNA interference RNA interference (RNAi) holds great promise for the development of ...

ProNAi Announces Preclinical Success for PNT2258 Therapeutic - Curative Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin's Lymphoma

... company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), today announced that its lead oncology therapeutic candidate, ... company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi(R)), which employs single strands of DNA to target and treat ...

Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer

... variety of primary cancer sites including breast and kidney. About RNA interference (RNAi) RNA interference (or RNAi) is a naturally occurring mechanism within cells for selectively ...

CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal

... 23, 2007 - CytRx Corporation (NASDAQ:CYTR) today announced that the RNA interference (RNAi) delivery technology exclusively licensed to its ... of the Carnegie Institution of Washington, toward the discovery of RNA interference was awarded the 2006 Nobel Prize in Physiology or Medicine, hailed as ...

Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus

... therapeutics to treat patients who become infected with RSV. About RNA interference (RNAi) RNA interference (or RNAi) is a naturally occurring mechanism within cells for selectively ...

Gemin X Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood

... Multiple myeloma is a type of cancer caused by malignant plasma cells that are spread throughout the bone marrow, resulting in bone erosion and interference with bone marrow and immune system function. MM is incurable and is characterized by frequent early responses to treatment followed by relapse. The ...